Latest news

• Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more

  NICE has published draft guidance recommending Pfizer’s Mylotarg (gemtuzumab ozogamicin) in combination with chemotherapy for newly diagnosed de novo CD33-positive acute myeloid leukaemia (AML) – but only if the disease ... That means Mylotarg

• Pfizer’s leukaemia drug Mylotarg backed for use in EU

  Pfizer’ s leukaemia drug Mylotarg backed for use in EU. The CHMP’s positive opinion could see the drug return to market after almost eight years. ... Pfizer kept producing Mylotarg in order to make it available on compassionate use in Europe and this

• Novartis claims FDA breakthrough status for leukaemia treatment

  Also waiting in the wings could be volasertib from Boehringer Ingelheim, which is currently in phase III clinical trials, and Pifzer's Mylotarg, which would be reintroduced to the market after

• Boehringer and Philogen collaborate on acute myeloid leukaemia

  Treatment options for AML are still somewhat limited, however at the end of last year Pfizer's Mylotarg (gemtuzumab ozogamcin) also showed itself to significantly improve overall survival compared to best

• ASH: Pfizer eyes re-launch of Mylotarg

  ASH: Pfizer eyes re-launch of Mylotarg. Data supports drug's use in acute myeloid leukaemia. ... We are engaging in discussions with the FDA and other health authorities to determine the best path forward for Mylotarg", he added.